On Aprl 5, 2022 Immix Biopharma, Inc. (Nasdaq: IMMX) ("ImmixBio" or the "Company"), a biopharmaceutical company pioneering Tissue Specific Therapeutics (TSTx)TM targeting oncology and immuno-dysregulated diseases, reported that management discussed key milestones, drug development timelines and the IMMX Advantage at its Milestone Day Event held at 9:30am ET on April 5, 2022 (Press release, Immix Biopharma, APR 5, 2022, View Source [SID1234611445]). The IMMX Milestone Day Event is viewable at www.immixbio.com/Apr2022MilestoneDay.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"At this Milestone Day Event, we are delighted to spotlight key stages of drug development, where we are in that process, and why we believe we are in an advantageous position in the biotechnology market with the $24.2 million raised in our IPO," said Ilya Rachman, MD PhD, CEO of ImmixBio. "We continue to be on track to kick-off 2 clinical trials in 2022 and obtain clinical data from both trials as well as remain open to new opportunities that present themselves."